HC Wainwright & Co. Reiterates Neutral on Chinook Therapeutics, Maintains $40 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Ed Arce reiterated a Neutral rating on Chinook Therapeutics (NASDAQ:KDNY) and maintained a $40 price target.
June 21, 2023 | 12:28 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
HC Wainwright & Co. analyst Ed Arce reiterated a Neutral rating on Chinook Therapeutics and maintained a $40 price target.
The news of HC Wainwright & Co. analyst Ed Arce reiterating a Neutral rating on Chinook Therapeutics and maintaining a $40 price target is directly related to KDNY. However, since the rating is neutral, it is not expected to have a significant impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100